128 related articles for article (PubMed ID: 32541631)
1. Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Hata T; Mizuma M; Motoi F; Iseki M; Omori Y; Hayashi H; Nakagawa K; Morikawa T; Kamei T; Naitoh T; Furukawa T; Unno M
Pancreas; 2020 Jul; 49(6):768-773. PubMed ID: 32541631
[TBL] [Abstract][Full Text] [Related]
2. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
5. An integrated analysis of host- and tumor-derived markers for predicting high-grade dysplasia and associated invasive carcinoma of intraductal papillary mucinous neoplasms of the pancreas.
Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Naitoh T; Furukawa T; Unno M
Surg Today; 2020 Sep; 50(9):1039-1048. PubMed ID: 32124086
[TBL] [Abstract][Full Text] [Related]
6. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
Das KK; Xiao H; Geng X; Fernandez-Del-Castillo C; Morales-Oyarvide V; Daglilar E; Forcione DG; Bounds BC; Brugge WR; Pitman MB; Mino-Kenudson M; Das KM
Gut; 2014 Oct; 63(10):1626-34. PubMed ID: 24277729
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Prognostic Impact of Neutrophil-to-Lymphocyte Ratio for Intraductal Papillary Mucinous Neoplasms of the Pancreas With High-Grade Dysplasia and Associated Invasive Carcinoma.
Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Takadate T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Furukawa T; Naitoh T; Unno M
Pancreas; 2019 Jan; 48(1):99-106. PubMed ID: 30540681
[TBL] [Abstract][Full Text] [Related]
8. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
9. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas.
You L; Ma L; Zhao WJ; Zhao YP; Dai MH
Clin Chim Acta; 2016 Feb; 454():89-93. PubMed ID: 26746574
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing Revealed TP53 Mutations to Be Malignant Marker for Intraductal Papillary Mucinous Neoplasms That Could Be Detected Using Pancreatic Juice.
Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Maekawa S; Mochizuki K; Kawaida H; Itakura J; Katoh R; Fujii H; Sato T; Enomoto N
Pancreas; 2017; 46(10):1281-1287. PubMed ID: 28930868
[TBL] [Abstract][Full Text] [Related]
12. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas.
Fritz S; Hackert T; Hinz U; Hartwig W; Büchler MW; Werner J
Br J Surg; 2011 Jan; 98(1):104-10. PubMed ID: 20949535
[TBL] [Abstract][Full Text] [Related]
13. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms.
Zhuge X; Zhou H; Chen L; Chen H; Chen X; Guo C
BMC Cancer; 2021 Nov; 21(1):1253. PubMed ID: 34800987
[TBL] [Abstract][Full Text] [Related]
14. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.
Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
Ann Surg; 2012 Mar; 255(3):517-22. PubMed ID: 22301608
[TBL] [Abstract][Full Text] [Related]
15. Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer.
Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Fukasawa Y; Kawakami S; Hayakawa H; Maekawa S; Mochizuki K; Kawaida H; Kono H; Itakura J; Sato T; Ichikawa D; Enomoto N
Pancreas; 2019 Sep; 48(8):1032-1040. PubMed ID: 31404021
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
[TBL] [Abstract][Full Text] [Related]
17. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Invasive Intraductal Papillary Mucinous Carcinoma of the Pancreas.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
JAMA Surg; 2017 Mar; 152(3):e165054. PubMed ID: 28122068
[TBL] [Abstract][Full Text] [Related]
19. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
20. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
